CNBC's Mike Huckman talks to Acorda Therapeutics CEO Ron Cohen at the annual meeting of the Generic Pharmaceutical Association about the rationale for charging $13,000 a year for its new multiple sclerosis drug Ampyra. Some large pharmaceutical companies recently have raised prices on drugs, as evidenced by the prices set for Ampyra and Auxilium's Xiaflex, Huckman says.

Full Story:

Related Summaries